Evidence map›Paper›PMID 40737412›Full record

ArticleScience advances2025

Morphology- and adhesion-dual biomimetic nanovaccine boosts antigen cross-presentation through subcellular transport regulation.

Zhenyu Wang, Huimin Zhou, Qianyi Su, Qinyu Qiu, Wenjia Deng, Miaomiao Zhang, Zhiyong Xu, Jiaxin Li, Jisheng Xiao, Xiaopin Duan

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhenyu WangDepartment of General Surgery, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.ORCID 0000-0002-2321-5536
Huimin ZhouDepartment of General Surgery, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Qianyi SuDepartment of General Surgery, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.ORCID 0009-0008-8216-0476
Qinyu QiuTranslational Medicine Research Center, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Wenjia DengDepartment of General Surgery, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Miaomiao ZhangDepartment of General Surgery, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Zhiyong XuDepartment of General Surgery, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Jiaxin LiDepartment of General Surgery, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.ORCID 0000-0003-2674-5388
Jisheng XiaoDepartment of General Surgery, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.ORCID 0000-0001-9904-3788
Xiaopin DuanDepartment of General Surgery, Zhujiang Hospital; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.ORCID 0000-0002-8713-6773

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In situ tumor vaccines have immense potential for immunotherapy because they generate whole tumor-derived antigens (TDAs) to activate antitumor immune responses. However, the rapid degradation and clearance of the released TDAs severely hinder subsequent antigen presentation and the final efficacy of the in situ vaccine. Here, we synthesized gold nanoxanthium coated with polydopamine (AuNX-PDA) to mimic the morphological and biological adhesion properties of xanthium and mussels, respectively. AuNX-PDA facilitated effective absorption of released TDAs after near-infrared II photothermal treatment and delivery of the absorbed TDAs to the endoplasmic reticulum and Golgi apparatus of dendritic cells for cross-presentation, thereby activating CD8

Indexed as

Antigen PresentationBiomimetic MaterialsCancer VaccinesCross-PrimingAnimalsAntigens, NeoplasmBiomimeticsCD8-Positive T-LymphocytesCell Line, TumorDendritic CellsFemaleGoldImmunotherapyIndolesMelanoma, ExperimentalMiceAntigens, NeoplasmCancer VaccinesGoldIndolesNanovaccinespolydopaminePolymers

Identifiers

PMID40737412
PMCPMC12309692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.